Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SCB-2019 COVID-19 Vaccine in Healthy Volunteers
NCT04405908Phase 1Completed
- Sponsor
- Clover Biopharmaceuticals
- Start
- Jun 2020
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCB-2019 in coronavirus disease 2019 (COVID-19) (27 arms), sponsored by Clover Biopharmaceuticals. Primary endpoints: Incidence of solicited adverse events at 7 days, Incidence of unsolicited adverse events and 3 more. Started Jun 2020; status: completed.
02
Drugs
SCB-2019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04405908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405908.